Sep Qtr 2026 headlined by EW-001 on the threshold of first US FDA advice, first Australian manufacturing run. Check out the full announcement and join in with the conversation at: investorhub.adalta.com.au/an… #1AD

More than A$1 million in additional R&D refunds anticipated: an Advance Overseas Finding confirms key EW-001 work conducted overseas is eligible for Australia’s R&D Tax Incentive. Check out the announcement, join the conversation at: investorhub.adalta.com.au/an… #1AD

EW-001 update: our Joint Development Committee with SHcell has approved the briefing pack for our FDA pre-IND meeting and how EW-001 will be made in Australia. First Australian manufacturing runs anticipated in 2H 2026. Join the conversation at: investorhub.adalta.com.au/an… #1AD

AdAlta opens a representative office in Shanghai. We are on the ground in the world’s most active source of cell therapy innovation, and where our next pipeline candidates will be found. Check out the full announcement, join the conversation at: investorhub.adalta.com.au/an… #1AD

Milestone reached: after review of '00s of documents, drafting a Phase 1 protocol and finalising manufacturing transfer plans, US FDA has accepted AdAlta’s request for a pre-IND meeting on EW-001. Join in with the conversation at: investorhub.adalta.com.au/an… #1AD

Big pharma validating our manufacturing strategy. Automation partner Oribiotech signed a 10y US$120m deal to move an approved cell therapy onto the IRO® platform – the same platform AdAlta has chosen. Join the conversation at: investorhub.adalta.com.au/an… #1AD

Check out our CAR-TCR Summit, Boston poster at: investorhub.adalta.com.au/an… #1AD

A bilingual (Chinese-English) investor deck is now on our investor hub. 一份中英雙語版投資人簡報現已發佈在我們的投資人專區。Read it here: investorhub.adalta.com.au/ac… #1AD

BZDS1901 special access scheme launch in China AdAlta’s partner, SHcell, has approval to provide BZDS1901 (EW-001) to advanced mesothelioma patients under a special access scheme in China.  Join the conversation at: investorhub.adalta.com.au/an… #1AD

We've just released the following announcement: EW-001 IIT study overall survival update The 5 patients still on study in March remain alive. At higher EW-001 doses, patients do better. For full announcement and to join the conversation: investorhub.adalta.com.au/an… #1AD

We've just released the following announcement: 2 year survival milestone for EW-001 patient 2 years cancer free is a significant survival milestone in advanced mesothelioma Check out the full announcement and join in with the conversation at: investorhub.adalta.com.au/an… #1AD

Further momentum for T cell therapies in solid cancers (like our EW-001 for advanced mesothelioma): "TECELRA’s full approval [by US FDA on 22 June 2026] is evidence that engineered T-cell therapies are beginning to establish a foothold in solid tumors" cellandgene.com/doc/full-fda…

We've just released the following announcement: Quarterly Appendix 4C and Activities Report "Continuing focus on execution of near term value milestones: building Australian manufacturing and engaging with the US FDA." Join the conversation at: investorhub.adalta.com.au/an… #1AD

Further validation of our "East to West" strategy. Novartis: China deals aren't a strategy shift — just where the science is endpoints.news/novartis-ceo-…

Visit our update ISCTANZ2026 "East to West" business model to view our ISCTANZ2026 poster describing the potential of our "East to West" cellular immunotherapy business model: investorhub.adalta.com.au/ac… #1AD

We've just released AdAlta's oral presentation and poster delivered at #ISCTANZ2026 held in Melbourne: ISCTANZ2026 presentation and poster Check out the full announcement, download the poster and join in with the conversation at: investorhub.adalta.com.au/an… #1AD

An abstract describing AdAlta's “East to West” business model has been selected for oral presentation at the ISCTANZ 2026 Regional Meeting in Melbourne (20-22 July 2026). Check out the announcement and join in with the conversation at: investorhub.adalta.com.au/an… #1AD

We've just released the following announcement: Oktopi AI collaboration for research efficiency @Oktopi collaboration enables us to test development plans with big pharma skill. Check out the full announcement and join in with the conversation at: investorhub.adalta.com.au/an… #1AD

We've just released the following announcement: Second BZDS1901 milestone paid AdAlta finalises initial financial commitment to BZDS1901, unlocking new data, critical materials. Check out the full announcement and join in with the conversation at: investorhub.adalta.com.au/an… #1AD

Congratulations CARsgen on approval of the 1st solid tumour CAR-T cell therapy. We've just posted this update on our investor hub: Solid cancer CAR-T arrives: world first approval to CARsgen Check out the full update and join the conversation at: investorhub.adalta.com.au/ac… #1AD